2023
DOI: 10.5826/dpc.1301a2
|View full text |Cite
|
Sign up to set email alerts
|

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(6 citation statements)
references
References 6 publications
0
6
0
Order By: Relevance
“…The patient journey, comorbidities, age, primary and node sites, symptoms, and the prevalence of either BCC or SCC behavior must be considered. In a few cases of locally advanced and metastatic BSCs, palliative chemotherapy has been used (adriamycine, cisplatin, carboplatin, paclitaxel) [61][62][63]. Kanzaky et al [61] presented a case report of metastatic BSC treated with adriamycine and cisplatin.…”
Section: Antitumoral Drugs: Chemotherapymentioning
confidence: 99%
“…The patient journey, comorbidities, age, primary and node sites, symptoms, and the prevalence of either BCC or SCC behavior must be considered. In a few cases of locally advanced and metastatic BSCs, palliative chemotherapy has been used (adriamycine, cisplatin, carboplatin, paclitaxel) [61][62][63]. Kanzaky et al [61] presented a case report of metastatic BSC treated with adriamycine and cisplatin.…”
Section: Antitumoral Drugs: Chemotherapymentioning
confidence: 99%
“…As far as concerns chemotherapy (CT) for laBSC and mBSC, there is no currently approved regimen. According to the literature, advanced BSCs were treated with a combination of paclitaxel and carboplatin 11,17 and intraarterial cisplatin (10 mg weekly for each carotid for 4 months, 400 mg in total) 12 . In general, CT was used after HHIs therapy, with the exception of one case (CT was preferred to vismodegib because the HHI was not reimbursed) 12 .…”
Section: Resultsmentioning
confidence: 99%
“…In a 61‐year‐old woman with a laBSC of the left shoulder and axilla infiltrating chest muscles and bones, previously treated with surgery and RT, vismodegib had to be discontinued because of intolerable side effects 17 . In addition, vismodegib turned out to be a failure in an 82‐year‐old male patient affected by a mBSC of the face with nodal and bone involvement: disease progression was observed at PET‐TC 3 months after starting therapy 11 . Among the patients treated at the Dermato‐Oncology Unit of Trieste, Patient E (Figure 3) was treated with vismodegib for 2 months with slight improvement, but the treatment was precociously discontinued after an ischemic stroke (Table 1 and Supplementary Material 1).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations